Curtis Foy, MD
Family Medicine · Easton, MDNPI 1679566079
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 75.4% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $19,593, more than ten times the $366 reported in 2019. Among family medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 555 payments — averaging $62.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$26K
- AbbVie$2K
- AstraZeneca$2K
- Mallinckrodt Hospital Products Inc.$819
- UCB, Inc.$802
- Radius Health, Inc.$540
- plus $3K from 32 others
What the payments were for
- Consulting fees$5,42016%
- Speaking & faculty fees$14,20041%
- Travel & lodging$2,3767%
- Food & beverage$12,37936%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 205 | $25,952 |
| AbbVie(2 entities) | 89 | $1,955 |
| AstraZeneca(2 entities) | 16 | $1,507 |
| Mallinckrodt Hospital Products Inc. | 32 | $819 |
| UCB, Inc. | 48 | $802 |
| Radius Health, Inc. | 24 | $540 |
| Lilly USA, LLC | 24 | $455 |
| Organon | 18 | $327 |
| Johnson & Johnson(2 entities) | 10 | $225 |
| Aurinia Pharma U.S., Inc. | 10 | $222 |
| Pfizer | 7 | $140 |
| Novartis | 5 | $108 |
| Kyowa Kirin, Inc. | 4 | $100 |
| GSK | 4 | $98 |
| Fresenius Kabi USA, LLC | 4 | $95 |
| Sobi, Inc | 4 | $90 |
| Sanofi-aventis U.S. LLC | 5 | $86 |
| Octapharma USA, Inc. | 3 | $72 |
| Boehringer Ingelheim | 3 | $67 |
| Lundbeck LLC | 3 | $59 |
| Invivyd Inc | 2 | $59 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Sanofi | 2 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Biogen | 2 | $51 |
| Sandoz | 3 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Novo Nordisk | 3 | $46 |
| Genentech USA, Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $42 |
| Pacira Therapeutics, Inc. | 1 | $40 |
| Alvogen Inc | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $33 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Supreme Orthopedic Systems, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,426 in reported general payments places this provider in the 95th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StrensiqAsfotase Alfa | 24 | $1,662,394 |
| TymlosAbaloparatide | 74 | $219,329 |
| ForteoTeriparatide | 19 | $80,362 |
| Teriparatide | 16 | $49,381 |
| Risedronate Sodium | 86 | $7,067 |
| Alendronate Sodium | 489 | $4,647 |
| Risedronate Sodium DrRisedronate Sodium | 20 | $2,403 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 24 | $628 |
| Raloxifene Hcl | 11 | $608 |
| Celecoxib | 16 | $413 |
| Pregabalin | 18 | $384 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 12 | $339 |
| Gabapentin | 12 | $310 |
| Hydrochlorothiazide | 20 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaStrensiq | $1,507 | $1,662,39424 claims |
| Radius Health, Inc.Tymlos | $540 | $219,32974 claims |
| Lilly USA, LLCForteo | $455 | $80,36219 claims |
| Alvogen IncTeriparatide | $38 | $49,38116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Easton
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
- Casey ScottCambridge$88K
- Daljeet SalujaBaltimore$63K
- Sanjay SaxenaHagerstown$60K
- Cynthia KleppingerSilver Spring$51K
- Tramaine DavisBowie$43K
- Alkesh PatelColumbia$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.